Newron Pharmaceuticals to Reveal Evenamide Insights at 2025 WCBP

Newron Pharmaceuticals S.p.A. will present significant data on its evenamide program as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP) in Berlin. The presentation will highlight the role of glutamate release modulation in enhancing treatment for patients inadequately responding to second-generation antipsychotics, including clozapine.

Study 008A suggests that evenamide improves efficacy when combined with existing antipsychotics, marking a promising development for treatment-resistant schizophrenia (TRS). This international study indicates that evenamide is well-tolerated without typical adverse effects. Additionally, the ENIGMA-TRS 1 study aims to assess evenamide’s long-term benefits, enrolling over 600 subjects internationally.

Newron's presentations will also address the safety and tolerability of new antipsychotics, emphasizing evenamide's unique mechanism of action. The company's insights are expected to contribute to a better understanding of therapeutic synergies in psychosis treatment.